Last reviewed · How we verify
Trastuzumab plus Pertuzumab (combination) (trastuzumab-plus-pertuzumab-combination)
At a glance
| Generic name | trastuzumab-plus-pertuzumab-combination |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Alopecia
- DIARRHOEA
- NAUSEA
- ALOPECIA
- Fatigue
- FATIGUE
- Anaemia
- Vomiting
- Neutropenia
- Asthenia
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (PHASE2)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer (PHASE2, PHASE3)
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (PHASE3)
- Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |